

Fig. 1

10 20 30 40 50
AUCACUCUCUUUAAUCACUACUCACAGUAACCUCAACUCCUGCCACAAUGUACAGGAU

70 80 90 100 110
AACUCCUGUCUUGCAUUGGCACUAAGUCUUGCACUUGUCACAAACAGUGGCACCUACUUC,
ACGTGATT CAGAACG TGAACAGT GTTT GTC
77-91 92-106

130 140 150 160 170
GUUCUACAAAGAAAACACAGCUACAACUGGAGCAUUUACUGCUGGAUUUACAGAUGAU

190 200 210 220 230
UGAAUGGAAUUAAUAAUUAACAAGAAUCCCAAACUCACCAGGAUGCUCACAUUUAAAGUU
ATGTTCTTAGGGTTT GAGTGGTCCTACGAG TGTAATTCAA
198-212 213-227 228-242

250 260 270 280 290
ACAUGCCCAAGGAAGGCCACAGAACUGAAACAUCUUCAGUGUCUAGAAGAAGAACUCA/
TGTACGGGTTCTTCCGG TCTTCTTGAGTT
243-257 287-301

310 320 330 340 350
CUCUGGAGGAAGUGCUAAAUUUAGCUCAAAGCAAAAACUUUCACUUAAGACCCAGGGA
GAGACCTCCTT CACGA GTGAATTCTGGGTCCCT
302-316 342-356

370 380 390 400 410
UAAUCAGCAUAUAUCAACGUAAUAGUUCUGGAACUAAAGGGAUCUGAAACAACAUUCAU
ATTAGTCGTTA
357-371

430 440 450 460 470
GUGAAUAUGCUGAUGAGACAGCAACCAUUGUAGAAUUUCUGAACAGAUGGAUUACCUU

490 500 510 520 530
GUCAAAGCAUCAUCUCAACACUAACUUGAUAAUUAAGUGCUUCCACUUAACAUUUC

550 560 570 580 590 600
GGCCUUCUAUUUAAUUUAAAUUUUAAUUUUAAUUUUAAUUGUUGAAUGUAUGGUUUGCUA

610 620 630 640 650 660
CCUAUUGUAAACUAUUAUUCUUAUUCUUAACUAUAAUAUGGAUCUUUUAUGAUUCUUL

670 680 690 700 710 720
UUGUAAGCCCUAGGGGCUCUAAAUGGUUUCACUUAUUUAUCCCAAUAUUUAUUUU

730 740 750 760 770 780
UGUUGAAUGUUAUAUAUAGUAUCUAUGUAGAUUGGUUAGUAAAACUAUUUAAUAAUUU

790 800
AUAAAUUAAAAAAAAAAAAAC

Fig.2

10 20 30 40 50 60
 GAUCGUUAGCUUCUCCUGAUAAACUAAUUGCCUCACAUUGUCACUGCAAUUCGACACCUA

 70 80 90 100 110 120
 UUA AUGGGUCUACCUCCCAACUGCUUCCCCUCUGUUCUCCUGCUAGCAUGUGCCGGC
 GAGTGGAGGGTTGACGAAGGGGGAGACAAGCG
 70-84 85-99

 130 140 150 160 170 180
 AACUUUGUCCACGGACACAAGUGCGAUUAUACCUUACAGGAGAUCAUCAAACUUUGAAC
 TTGAAACAGGTGCCTGTGTTACAGCTATACTTG
 119-133 134-148

 190 200 210 220 230 240
 AGCCUCACAGAGCAGAAGACUCUGUGCACCGAGUUGACCGUAACAGACAUCUUUGCUGCC
 TCGGAGTGTCTCGTCTTCTGAGACA
 176-190 191-205

 250 260 270 280 290 300
 UCCAAGAACACAACUGAGAAGGAAACCUUCUGCAGGGCUGCGACUGUGCUCCGGCAGUUC
 TGGAAGACGTCCCGACGCTGACACGAGGCC
 265-279 280-294

 310 320 330 340 350 360
 UACAGCCACCAUGAGAAGGACACUCGCGUGCCUGGGUGCGACUGCACAGCAGUUCCACAGG

 370 380 390 400 410 420
 CACAAGCAGCUGAUCCGAUCCUGAAACGGCUCGACAGGAACCUCUGGGGCCUGGCGGGC
 GCTAAGGACTTTGCCGAGCTGTCTTGAG
 376-390 391-405

 430 440 450 460 470 480
 UUGAAUUCUGUCCUGUGAAGGAAGCCAACCAGAGUACGUUGGAAAACUUCUUGGAAAGG

 490 500 510 520 530 540
 CUAAGACGAUCAUGAGAGAGAAUUAUCAAAGUGUUCGAGCUGAAUUAUUUAUUUAUG

 550 560 570 580 590 600
 AGUUUUUGAUAGCUUUUUUUUAAGUAUUUAUUAUUUAUAACUCAUAAAAUAAAG

 610
 UAUAUAUAGAAUCUAAAA

Fig.3




Fig.4




Fig.5




Fig.6




Fig.7




Fig.8




Fig.9




Fig.10




Fig.11




Fig.12




Fig.13

IL-2 342-356




Fig.14

IL-2 357-371




Fig.15

IL-4 119-133




Fig.16

IL-4 134-148




Fig.17

IL-4 265-279




Fig.18

IL-4 280-294





Fig. 19



¹ Time after adding 10 nM PMA, 0.5 mg/ml anti-human CD3 antibody and anti-human CD28 antibody to cultured Jurkat E6-1 cells

² The concentration of IL-2 in the culture supernatants measured by ELISA using anti-human IL-2 antibody

^{3, 4} Determination of cellular IL-2 expression level by dot blotting using RNA probe complementary to human IL-2 mRNA

Fig.20









DIG-11-dUTP & Reverse transcriptase		IL-2 expression	
Oligonucleotide		(+)	(-)
none	none		
none	none		
added	oligo dA		
added	oligo dT		

Fig.21

PROBE	IL-2 EXPRESSION			
	(+)		(-)	
IL-2 228-242(D)				
IL-2 243-257(A)				
IL-2 198-212(D)				
IL-2 213-227(A)				
IL-2 77-91(D)				
IL-2 92-106(A)				
IL-2 287-301(D)				
IL-2 302-316(A)				
IL-2 342-356(D)				
IL-2 357-371(A)				
NONE				

Fig.22




Fig.23

PROBE	IL-2 EXPRESSION					
	(+)			(-)		
IL-2 228-242(D) & IL-2 243-257(A)	D/A	A/A	D/D	D/A	A/A	D/D
IL-2 198-212(D) & IL-2 213-227(A)						
IL-2 77-91(D) & IL-2 92-106(A)						
IL-2 287-301(D) & IL-2 302-316(A)						
IL-2 342-356(D) & IL-2 357-371(A)						
NONE & NONE						

Fig. 24




Fig.25




Fig.26




Fig.27




Fig.28




Fig.29




Fig.30




Fig.31




Fig.32




Fig.33




Fig.34




Fig.35




Fig.36




Fig.37




Fig.38




Fig.39




Fig.40




Fig.41




Fig.42




Fig.43




Fig.44




Fig.45




Fig.46




Fig.47




Fig.48




Fig.49





Fig.50



Title: Method For Selectively Separating Live Cells Expressing A Specific Gene


Inventors: ISHIBASHI et al.

Attorney: JAMES H. HANCOCK, JR.

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.51



結論

[illegible]

Fig.53

IL-2 mRNA (+); 8/8



202-737-6770

Fig.54




Fig.55




Fig.56




Fig.57




Fig.58




Fig.59




Fig.60




Fig.61




Fig.62




Fig.63




Fig.64




Fig.65




Fig.66




Fig.67




Fig.68




Fig. 69




Fig.70




Fig.71




Fig.72




Fig.73




Fig.74




Fig.75




Fig.76




Fig.77




Fig.78




Fig.79




Fig.80




Fig.81




Fig.82




Fig.83




Fig.84




Fig.85




Fig.86

IL-2 mRNA (+); 5/24

IL-4 mRNA (+); 3/43

[illegible]

Fig. 87

IL-2 mRNA (+); 11/11	γ -IF mRNA (+); 14/14	TNF- β mRNA (+); 11/11
IL-4 mRNA (+); 0/10	IL-5 mRNA (+); 0/11	IL-10 mRNA (+); 0/9

Fig.88

IL-2 mRNA (+); 6/28

IL-4 mRNA (+); 3/42

400684-3506260

Fig. 89

IL-2 mRNA (+); 0/11	γ -IF mRNA (+); 0/11	TNF- β mRNA (+); 0/9
IL-4 mRNA (+); 12/12	IL-5 mRNA (+); 11/11	IL-10 mRNA (+); 11/11

Fig.90




Fig. 91





Fig.92



400684-3 6770

Fig. 93

IL-2 mRNA (+); 0/7	γ -IF mRNA (+); 0/8	TNF- β mRNA (+); 0/8
IL-4 mRNA (+); 9/9	IL-5 mRNA (+); 10/10	IL-10 mRNA (+); 9/9

Fig.94

